Comment on Makrinioti H et al.

Abstract

To the Editor, We read with great interest the article titled "The role of respiratory syncytial virus-and rhinovirus-induced bronchiolitis in recurrent wheeze and asthma-A systematic review and meta-analysis" published in the recent issue of the Pediatr Allergy Immunol. This article is the first to compare between-virus differences in the magnitude of virus-recurrent wheeze and virus-childhood asthma outcomes. The authors concluded that rhinovirus-induced bronchiolitis was more closely associated with the risk of developing wheezing and childhood asthma. 1 We would like to revisit this article from a validation perspective to further refine this important study.The authors searched the following five databases for target articles: PubMed, Google Scholar, Embase, the Cochrane Library, and the Scopus database. However, we recommend that authors should emphasize the inclusion of articles in English only, so as to avoid searches of databases in other languages. At the same time, the search scope of English databases should be expanded, and other commonly used databases such as Web of Science, PsycINFO, NLM Gateway, and Clini calTr ial.gov should also be searched.ZHANG et al.

Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer

“…The remaining 89 full-text articles were evaluated for eligibility, 62 of which were removed because they provided outdated preliminary results or lacked valid data. Thus, 27 prospective studies were included in the final qualitative and quantitative synthesis (Figure 1). The geographic distribution of included studies is shown in eFigure 1 in the Supplement.…”

“…Overall, the 27 trials included 815 patients with esophageal cancer being treated with neoadjuvant immunotherapy combined with chemotherapy who were available for analysis. All studies were open-label, phase 2 non-RCTs, and 25 of them were single-group and 2 were dual-group trials . Twenty-three trials enrolled patients with ESCC and applied anti–PD-1 antibody.…”

“…In the present study, neoadjuvant immunotherapy demonstrated promising results for patients with esophageal cancer. According to 24 trials with 615 patients with esophageal cancer, the pooled pCR rate was 31.4% (95% CI, 27.6%-35.3%), with no significant heterogeneity (Figure 2). Meanwhile, based on 17 trials, the pooled MPR rate was 48.9% (95% CI, 42.0%-55.9%), with mild heterogeneity ( I 2 = 50.3%; 95% CI, 13.1%-71.5%; P = .10) (Figure 3).…”

“…According to 24 trials with 615 patients with esophageal cancer, the pooled pCR rate was 31.4% (95% CI, 27.6%-35.3%), with no significant heterogeneity (Figure 2). Meanwhile, based on 17 trials, the pooled MPR rate was 48.9% (95% CI, 42.0%-55.9%), with mild heterogeneity ( I 2 = 50.3%; 95% CI, 13.1%-71.5%; P = .10) (Figure 3). In terms of safety, 14 trials, including 452 patients, reported the incidence of trSAE; the pooled level was 26.9% (95% CI, 16.7%-38.3%), with significant heterogeneity ( I 2 = 84.9%; 95% CI, 76.2%-90.4%; P < .001) (eFigure 9 in the Supplement).…”

Multidrug nanomedicine

“…Co-formulating two mRNAs in one LNP, instead of co-administering two LNP single-loaded with one mRNA, would in principle be possible, but this likely doesn't add much value in vaccination setups. When it comes to simultaneously producing proteins at the single-cell level, however, it has been shown that 'together is better', especially when aiming to ratiometrically control protein expression 2 . Co-formulating two RNAs in one LNP is furthermore crucial for efficient CRISPR-based gene editing.…”